+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Perampanel"

From
Anticonvulsants Market Report 2025 - Product Thumbnail Image

Anticonvulsants Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Epilepsy Treatment - Global Strategic Business Report - Product Thumbnail Image

Epilepsy Treatment - Global Strategic Business Report

  • Report
  • June 2025
  • 483 Pages
  • Global
From
Epilepsy Drugs - Global Strategic Business Report - Product Thumbnail Image

Epilepsy Drugs - Global Strategic Business Report

  • Report
  • June 2025
  • 93 Pages
  • Global
From
From
From
From
Seizures Pipeline Insight Analysis Report - Product Thumbnail Image

Seizures Pipeline Insight Analysis Report

  • Drug Pipelines
  • August 2024
  • 150 Pages
  • Global
From
From
From
From
From
  • 15 Results (Page 1 of 1)
Loading Indicator

Perampanel is a drug used to treat seizures associated with epilepsy. It is a non-competitive antagonist of the AMPA receptor, which is a type of glutamate receptor found in the central nervous system. Perampanel is the first and only drug of its kind to be approved by the US Food and Drug Administration (FDA). It is available in tablet form and is taken orally. Perampanel is used as an adjunctive therapy for partial-onset seizures in adults and adolescents aged 12 years and older. It is also used as an adjunctive therapy for primary generalized tonic-clonic seizures in adults and adolescents aged 12 years and older. The market for perampanel is growing as more people are being diagnosed with epilepsy and other seizure disorders. It is an important drug in the treatment of these conditions and is becoming increasingly popular due to its effectiveness and safety profile. Companies in the perampanel market include Eisai Co., Ltd., UCB Pharma, and Sunovion Pharmaceuticals. Show Less Read more